HAS reimburses iptacopan for second-line use only and ravulizumab first-line, so the two agents enter CEPS price negotiation from structurally different positions.
France assesses medicines on two separate scales. SMR (Service Médical Rendu) sets reimbursement eligibility and the statutory reimbursement rate; ASMR (Amélioration du Service Médical Rendu) anchors the price CEPS negotiates. For PNH, the Commission de la Transparence issued a favourable reimbursement opinion for iptacopan (Fabhalta) only in adults with symptomatic haemolytic anaemia after at least six months on a C5 complement inhibitor, and an unfavourable opinion for the other situations its marketing authorisation covers. Ravulizumab (Ultomiris) holds the opposite position: a favourable opinion with first-line positioning, on the strength of its every-eight-week dosing against eculizumab's every-two-week schedule, rather than any demonstrated efficacy or tolerance advantage.
That asymmetry, not price, is what separates the two commercially. Iptacopan has to earn its way in from second line, behind a prior-treatment gate that removes every treatment-naive patient from its addressable population before a price is ever discussed. Ravulizumab defends an unrestricted first-line population. HAS also published a separate economic opinion on iptacopan on 5 December 2024, assessing its efficiency against a mixed comparator arm of C5 inhibitors. The specific ASMR level granted and the negotiated CEPS prices for both agents could not be established in the public record available to us, and are deliberately not stated here rather than estimated.
France's PNH reimbursement position by agent — ravulizumab first-line versus iptacopan second-line only
| Agent | Reimbursement opinion | Position | Eligibility gate |
|---|---|---|---|
| Ultomiris (ravulizumab) | Favourable | First-line | None within the reimbursed indication |
| Fabhalta (iptacopan) | Favourable for second-line only; unfavourable for other situations in the marketing authorisation | Second-line | Symptomatic haemolytic anaemia after ≥6 months on a C5 inhibitor |
Sources: HAS Commission de la Transparence, FABHALTA (iptacopan) — hémoglobinurie paroxystique nocturne; HAS, Avis économique FABHALTA (iptacopan), 5 décembre 2024; HAS Commission de la Transparence, ULTOMIRIS (ravulizumab).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The SMR mechanism (reimbursement eligibility) versus ASMR (price-negotiation anchor)
- how the Commission de la Transparence positioned each agent and why
Delivers
- The prior-treatment gate and the patients it removes
- how a restricted indication changes CEPS negotiation leverage for a specialty oral
Delivers
- Ravulizumab's first-line comparator status and the dosing-convenience rationale behind it
- the access bar a new entrant competing for first line must clear
Custom brief delivered in 72 hours.
Assess this reportWhat's inside
- How SMR sets reimbursement eligibility and ASMR anchors CEPS price negotiation
- Where ravulizumab and iptacopan sit on each scale
- The every-8-week dosing advantage HAS cited
- First-line comparator implications for new entrants
- The ≥6-month prior anti-C5 eligibility gate
- The Commission de la Transparence opinion and the separate 5 December 2024 economic opinion
- How CEPS anchors price to the ASMR rating, target population and European reference prices
- Why a restricted indication changes the negotiation before a price is tabled
- How French published prices feed other countries' international reference-pricing baskets
- Why CEPS's European-reference-price lever adds cascade risk beyond the SMR/ASMR ratings
- Why ravulizumab's unrestricted first-line position contrasts with iptacopan's second-line-only reimbursement
- How the two indications define two distinct competitive footholds in France
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources — HAS Commission de la Transparence opinions and live CEPS pricing documentation, not secondary summaries. Findings are independently verified before inclusion.
PNH France Payer & HTA sources: HAS Commission de la Transparence records for iptacopan and ravulizumab, and HAS's economic opinion on iptacopan of 5 December 2024. Figures that could not be traced to a primary source — the ASMR level granted and the negotiated CEPS prices — are omitted rather than estimated.
- Iptacopan's second-line-only reimbursement opinion and its ≥6-month prior anti-C5 criterion verified against the live HAS Commission de la Transparence record
- Ravulizumab's first-line positioning verified against HAS Commission de la Transparence documentation
- The ASMR level granted and the negotiated CEPS prices could not be established in the public record, and are omitted rather than estimated
Frequently asked questions
Commission this assessment
AXLRx PNH Payer & HTA — France is built for market access and payer teams that need a rigorous characterisation of the French SMR/ASMR framework and CEPS pricing dynamics. Custom brief in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.